Kifaru is used for the treatment of erectile dysfunction
Molecule: Sildenafii citrate
Formulation: Sildenafii 50mg/100mg Tablets
Packaging Unit: 2 Tablets, 4 Tablets
Dosage: The recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. However, Kifaru may be taken anywhere from 4 hours to 0.5 hour before sexual activity. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100mg or decreased to 25mg. The maximum recommended dosing frequency is once per day.
Kifaru (Sildenafil Citrate) is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).
Inhibitor of phosphodiesterase (type V). Treatment of Erectile dysfunction.
Mechanism Of Action
Kifaru has physiologic mechanism of erection of the penis which involves release of nitric oxide in the corpus cavernosum during sexual stimulation. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Kifaru has no direct relaxant effect on isolated human corpus cavernosum, but enhances the effect of nitric oxide by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. When sexual stimulation causes local release of nitric oxide, inhibition of PDE5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil at recommended doses has no effect in the absence of sexual stimulation. Studies in vitro have shown that Kifaru is selective for PDE5.
Kifaru is generally well tolerated. Some times Kifaru causes headache, flushing, dyspepsia, nasal congestion, abnormal vision, diarrhea, dizziness and rashes.
Kifaru was shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using organic nitrates, either regularly and/or intermittently, in any form, is therefore contraindicated. It is contraindicated in patients with a known hypersensitivity to any component of the preparation.
Sildenafil must be used with caution in patients suffering from cardiac insufficiency, unstable angina, renal and hepatic insufficiency and in patients taking several hypotensive drugs